Who are NAFT-500's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mentax.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/naft-500.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

NAFT-500 — Competitive Intelligence Brief

NAFT-500 (NAFT-500) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Benzylamine antifungal. Area: Dermatology.

phase 3 Benzylamine antifungal Fungal sterol synthesis (squalene epoxidase inhibition) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

NAFT-500 (NAFT-500) — Merz North America, Inc.. NAFT-500 is a naftifine derivative designed to modulate skin barrier function and reduce inflammation in dermatological conditions.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
NAFT-500 TARGET	NAFT-500	Merz North America, Inc.	phase 3	Benzylamine antifungal	Fungal sterol synthesis (squalene epoxidase inhibition)
Mentax	BUTENAFINE	Bayer	marketed	Benzylamine Antifungal	Cytochrome P450 2D6	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Benzylamine antifungal class)

Merz North America, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NAFT-500 — Competitive Intelligence Brief. https://druglandscape.com/ci/naft-500. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab